Postoperative Pain Following Eye Enucleation: A Prospective Observational Study.

Enucleation of an eye is the most invasive procedure in ophthalmologic surgery. It can be the result of various diseases (malignant/chronic/trauma/infection) and is nevertheless relatively rare, but leads to the loss of a strongly innervated neuronal organ. This study systematically evaluates postoperative pain levels following enucleation of the eye globe.

Electricity consumption of anesthesia workstations and potential emission savings by avoiding standby.

Background: Anesthesiology has a relevant carbon footprint, mainly due to volatile anesthetics (scope 1 emissions). Additionally, energy used in the operating theater (scope 2 emissions) contributes to anesthesia-related greenhouse gas (GHG) emissions.

Objectives: Optimizing the electricity use of medical devices might reduce both GHG emissions and costs might hold potential to reduce anaesthesia-related GHG-emissions and costs.

[Pain therapy in children following ophthalmic surgery].

Pain following eye surgery is often described as being relatively moderate; however, there are also procedures that lead to a pronounced pain experience. Particularly in pediatric patients, pain therapy is often insufficient due to a lack of knowledge and fear of complications. These individual and organizational deficits lead to unnecessary discomfort for children and parents.

Severe Hypotension With Concomitant Sodium-Glucose Co-Transporter-2 Inhibitor and Angiotensin Receptor-Neprilysin Inhibitor Therapy in a Patient With Heart Failure Reduced Ejection Fraction: A Case Report.

Large cardiovascular outcomes trials in individuals with heart failure, with and without diabetes, have demonstrated a significant risk reduction in the composite outcome of cardiovascular death or hospitalizations for heart failure with SGLT2 inhibitor therapy. These positive outcomes have led to the recommendation that SGLT2 inhibitors serve as backbone therapy in patients with heart failure reduced ejection fraction (HFrEF). To date, there has not been enough participants in clinical trials on concomitant SGLT2 inhibitor and angiotensin receptor-neprilysin inhibitor therapy to evaluate the benefits and risks of combination therapy with these two agents outside of smaller subgroup analyses.

A misdiagnosis of type 2 diabetes mellitus: Using continuous glucose monitoring to improve patient-centered care.

Background: The American Diabetes Association recommends glycosylated hemoglobin (A1C) to assess the management of diabetes mellitus (DM) and provides specific A1C goals to reduce the risk of DM-related complications. Although A1C is a convenient test to diagnose and monitor DM management over a 3-month time frame, certain conditions may affect the accuracy of the A1C.

Case Summary: This case describes a woman diagnosed as having type 2 DM based on multiple A1C levels > 10%.

Cultivating best practices in care transitions through comprehensive medication management.

An estimated 20% of patients experience a postdischarge adverse event in the 30 days after hospital discharge, with approximately two-thirds of these events considered preventable or ameliorable. Numerous transitional care interventions have been developed and implemented by clinical pharmacists to reduce postdischarge adverse drug events and readmissions; however, most efforts are focused on the admission and discharge process. Low-quality evidence and mixed results from evaluations of postdischarge interventions have left health care organizations unsure which interventions provide the greatest value and how to optimize their implementation.

Characterization of Risk Factors for Genitourinary Infections with Sodium-Glucose Cotransporter-2 Inhibitors.

Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are associated with an increased risk of genitourinary infections in patients with type 2 diabetes mellitus (T2DM). It is unknown which factors may predispose patients to an increased risk of developing a genitourinary infection.

Objective: To evaluate whether hemoglobin A1c levels and other patient-specific factors at initiation of SGLT2 inhibitor therapy were a predictor for increased risk for genitourinary infections.

Severe Hyponatraemia Associated with the Use of Arginine-Vasopressin in Two Neonates with Complex Congenital Heart Disease.

We report two cases of neonates with complex congenital heart disease and volume, catecholamine, and corticosteroid refractory shock treated with arginine-vasopressin. Arginine-vasopressin was able to reverse critical hypotension, but both patients developed severe hyponatremia, which recovered after discontinuation of arginine-vasopressin. Close control and prompt substitution of serum sodium is required in neonates with advanced heart failure on high-dose vasopressin therapy.

SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.

Study Objective: Currently only minimal information is available regarding risk factors for the development of sodium glucose cotransporter-2 inhibitor (SGLT2i)-related diabetic ketoacidosis (DKA). We aim to identify individual patient characteristics associated with cases of SGLT2i-related DKA to better describe potential risk factors.

Design: Systematic review of primary literature.